Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université´ D'aix-Marseille

Université Claude Bernard

Centre Leon Bernard

Virginie Millet

Jean-Yves Blay

Philippe Naquet

Caroline Giessner

Franck Galland

Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.

Use of VNN1 as a biomarker and a therapeutic target in sarcomas

Growing community of inventors

Marseilles, France

Virginie Millet